TuisGBM • FRA
add
Inovio Pharmaceuticals Inc
Vorige sluiting
€1,56
Dagwisseling
€1,57 - €1,57
Jaarwisseling
€1,57 - €12,14
Markkapitalisasie
63,43 m USD
Gemiddelde volume
265,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 116,99 k | 13,97% |
Bedryfskoste | 7,60 m | 37,12% |
Netto inkomste | -19,38 m | 22,48% |
Netto winsgrens | -16,57 k | 31,99% |
Wins per aandeel | -0,60 | 89,42% |
EBITDA | -19,95 m | 9,81% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 94,11 m | -35,23% |
Totale bates | 113,20 m | -33,78% |
Totale aanspreeklikheid | 44,69 m | -16,62% |
Totale ekwiteit | 68,50 m | — |
Uitstaande aandele | 36,67 m | — |
Prys om te bespreek | 0,82 | — |
Opbrengs op bates | -46,24% | — |
Opbrengs op kapitaal | -61,22% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -19,38 m | 22,48% |
Kontant van bedrywe | -19,66 m | 25,16% |
Kontant van beleggings | 34,64 m | 73,71% |
Kontant van finansiering | 29,15 m | 1 485,47% |
Netto kontantverandering | 44,13 m | 1 081,94% |
Beskikbare kontantvloei | 3,91 m | 127,61% |
Meer oor
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
Gestig
1999
Webwerf
Werknemers
134
